# Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib

> **NCT01478373** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 39 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Dovitinib (TKI258)

## Key facts

- **NCT ID:** NCT01478373
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478373, "Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01478373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*